文献速递肺外科食管与纵隔外科

肺移植受者Barrett食管的患病率与自然史:单中心经验

Prevalence and Natural History of Barrett's Esophagus in Lung Transplant: A Single-Center Experience.
PubMed 文献 · Ann Thorac Surg · 2018-11-24

该单中心回顾性研究分析了2010至2016年466例肺移植患者,发现54例(11.59%)移植前存在Barrett食管。中位随访29.48个月期间,3例进展为低级别发育不良或食管腺癌,进展率为每患者年2.3%。结论提示肺移植受者Barrett食管患病率较高且进展风险增加,可能需要更密集的内镜监测。

要点

  • 肺移植受者移植前Barrett食管患病率为11.59%(54/466)。
  • Barrett食管向发育不良或食管腺癌的进展率为每患者年2.3%。
  • 免疫抑制患者中高级别发育不良可能快速进展,需加强内镜监测。

核心结论

  • Barrett食管在肺移植受者中似乎比一般人群更常见。
  • 肺移植后Barrett食管向食管腺癌进展的风险较高,高级别发育不良在免疫抑制患者中可能快速进展。
  • 肺移植后Barrett食管患者可能需要更密集的监测内镜。

研究设计与样本

  • 单中心回顾性研究,纳入2010年1月1日至2016年10月31日在Norton胸科研究所接受肺移植的患者。
  • 共分析466例肺移植患者,其中54例(11.59%)移植前内镜检出Barrett食管。
  • 分析移植前食管造影、食管胃十二指肠镜、24小时pH监测、高分辨率测压和胃排空研究。

主要发现

  • 54例Barrett食管患者中位年龄64岁(四分位距58.25至68.75岁),66.7%为男性。
  • 中位随访29.48个月(四分位距19.69至37.98个月),16例(29.62%)移植后接受抗反流手术。
  • 3例患者在移植后监测中进展为低级别发育不良或食管腺癌,进展率为每患者年2.3%。
  • 1例患者再移植后24个月诊断高级别发育不良,完全内镜消融后5个月无发育不良,但最终复发并因浸润癌接受食管切除术。
  • 2例患者分别在肺移植后7个月和13个月诊断低级别发育不良,均成功接受射频消融治疗。

临床怎么用

  • 对肺移植候选者应关注Barrett食管的筛查与移植后监测。
  • 肺移植后Barrett食管患者可考虑更密集的内镜监测以早期发现发育不良或癌变。

局限性

  • 单中心回顾性设计,样本量有限。
  • 随访时间中位数约29个月,可能不足以观察长期进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Barrett's esophagus (BE)-intestinal metaplasia in the esophagus-may progress to low-grade dysplasia (LGD), high-grade dysplasia (HGD), and ultimately, invasive esophageal adenocarcinoma (EAC). The course of BE in immunosuppressed lung transplant recipients is unknown. METHODS: This study retrospectively reviewed the records of patients who underwent lung transplant at a single center, Norton Thoracic Institute in Phoenix, Arizona, between January 1, 2010 and October 31, 2016. Pretransplant esophagram, esophagogastroduodenoscopy, 24-hour pH monitoring, high-resolution manometry, and gastric emptying studies were analyzed. RESULTS: Of the 466 patients who underwent lung transplant during the study period, 54 (11.59%) had BE on pretransplant esophagogastroduodenoscopy. Of these, 1 patient had HGD before lung transplant. The median age of patients was 64 years (interquartile range, 58.25 to 68.75 years); 66.7% were men. Median follow-up duration was 29.48 months (interquartile range, 19.69 to 37.98 months). Sixteen of 54 patients (29.62%) underwent antireflux surgery after lung transplant. LGD or EAC developed in 3 patients during posttransplant surveillance. One patient had a diagnosis of HGD 24 months after retransplant. She underwent complete endoscopic ablation and was dysplasia-free for 5 months, but ultimately the condition recurred, and she underwent esophagectomy for invasive cancer. Two patients had a diagnosis of LGD 7 and 13 months after lung transplant and were successfully treated with radiofrequency ablation. The rate of progression to dysplasia or EAC was 2.3% per patient-year. CONCLUSIONS: BE seems to be more prevalent in lung transplant recipients than in the general population. The study findings suggest that patients with BE have a higher risk of BE-to-EAC progression after lung transplant and that HGD may progress rapidly in immunosuppressed patients. More intensive surveillance endoscopy may be required in patients with BE after lung transplant.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Biswas Roy S, Banks P, Kunz M, et al. Prevalence and Natural History of Barrett's Esophagus in Lung Transplant: A Single-Center Experience. Ann Thorac Surg. 2018. PMID: 30481513. doi:10.1016/j.athoracsur.2018.10.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。